Filing Details

Accession Number:
0001213900-25-054753
Form Type:
13D Filing
Publication Date:
2025-06-15 20:00:00
Filed By:
dievini Hopp BioTech holding GmbH & Co. KG
Company:
Curevac N.v. (NASDAQ:CVAC)
Filing Date:
2025-06-16
SEC Url:
13D Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
dievini Hopp BioTech holding GmbH & Co. KG 0 70,181,760 0 70,181,760 70,181,760 31.3%
DH-LT-Investments GmbH 0 8,753,595 0 8,753,595 8,753,595 3.9%
DH-Capital GmbH & Co. KG 0 70,181,760 0 70,181,760 70,181,760 31.3%
OH Beteiligungen GmbH & Co. KG 0 70,181,760 0 70,181,760 70,181,760 31.3%
Dietmar Hopp 33,517 82,340,027 33,517 82,340,027 82,373,544 36.7%
Oliver Hopp 0 70,181,760 0 70,181,760 70,181,760 31.3%
Daniel Hopp 0 70,181,760 0 70,181,760 70,181,760 31.3%
DHFS II Holding GmbH & Co. KG 0 8,753,595 0 8,753,595 8,753,595 3.9%
Zweite DH Verwaltungs GmbH 0 3,404,672 0 3,404,672 3,404,672 1.5%
Filing





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D



Comment for Type of Reporting Person:
Item 13. This percentage is calculated based on 224,338,257 common shares of CureVac N.V. outstanding as set forth in its Annual Report on Form 20-F filed by the Issuer with the SEC on April 11, 2025 (the "Annual Report").


SCHEDULE 13D



Comment for Type of Reporting Person:
Item 13. This percentage is calculated based on 224,338,257 common shares of CureVac N.V. outstanding as set forth in its Annual Report.


SCHEDULE 13D



Comment for Type of Reporting Person:
Item 13. This percentage is calculated based on 224,338,257 common shares of CureVac N.V. outstanding as set forth in its Annual Report.


SCHEDULE 13D



Comment for Type of Reporting Person:
Item 13. This percentage is calculated based on 224,338,257 common shares of CureVac N.V. outstanding as set forth in its Annual Report.


SCHEDULE 13D



Comment for Type of Reporting Person:
Item 13. This percentage is calculated based on 224,338,257 common shares of CureVac N.V. outstanding as set forth in its Annual Report.


SCHEDULE 13D



Comment for Type of Reporting Person:
Item 13. This percentage is calculated based on 224,338,257 common shares of CureVac N.V. outstanding as set forth in its Annual Report.


SCHEDULE 13D



Comment for Type of Reporting Person:
Item 13. This percentage is calculated based on 224,338,257 common shares of CureVac N.V. outstanding as set forth in its Annual Report.


SCHEDULE 13D



Comment for Type of Reporting Person:
Item 13. This percentage is calculated based on 224,338,257 common shares of CureVac N.V. outstanding as set forth in its Annual Report.


SCHEDULE 13D



Comment for Type of Reporting Person:
Item 13. This percentage is calculated based on 224,338,257 common shares of CureVac N.V. outstanding as set forth in its Annual Report.


SCHEDULE 13D

 
dievini Hopp BioTech holding GmbH & Co. KG
 
Signature:/s/ Dr. Christina Eschenfelder
Name/Title:Dr. Christina Eschenfelder/Attorney-in-fact
Date:06/16/2025
 
DH-LT-Investments GmbH
 
Signature:/s/ Dr. Christina Eschenfelder
Name/Title:Dr. Christina Eschenfelder/Attorney-in-fact
Date:06/16/2025
 
DH-Capital GmbH & Co. KG
 
Signature:/s/ Dr. Christina Eschenfelder
Name/Title:Dr. Christina Eschenfelder/Attorney-in-fact
Date:06/16/2025
 
OH Beteiligungen GmbH & Co. KG
 
Signature:/s/ Dr. Christina Eschenfelder
Name/Title:Dr. Christina Eschenfelder/Attorney-in-fact
Date:06/16/2025
 
Dietmar Hopp
 
Signature:/s/ Dr. Christina Eschenfelder
Name/Title:Dr. Christina Eschenfelder as attorney-in-fact
Date:06/16/2025
 
Oliver Hopp
 
Signature:/s/ Dr. Christina Eschenfelder
Name/Title:Dr. Christina Eschenfelder as attorney-in-fact
Date:06/16/2025
 
Daniel Hopp
 
Signature:/s/ Dr. Christina Eschenfelder
Name/Title:Dr. Christina Eschenfelder as attorney-in-fact
Date:06/16/2025
 
DHFS II Holding GmbH & Co. KG
 
Signature:/s/ Dr. Christina Eschenfelder
Name/Title:Dr. Christina Eschenfelder/Attorney-in-fact
Date:06/16/2025
 
Zweite DH Verwaltungs GmbH
 
Signature:/s/ Dr. Christina Eschenfelder
Name/Title:Dr. Christina Eschenfelder/Attorney-in-fact
Date:06/16/2025